ClinicalTrials.gg
RecruitingNCT03606200CH-PCDUpdated Nov 25, 2025

Swiss Primary Ciliary Dyskinesia Registry

An observational study in Primary Ciliary Dyskinesia and Kartagener Syndrome, sponsored by University of Bern. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2025-11-25.

Primary conditionKartagener SyndromeRegistry: Ciliary Motility DisordersReclassifiedWhy we changed it
Registry
Ciliary Motility Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kartagener Syndrome
Why
  1. The study's listed conditions name Kartagener Syndrome, a narrower term within Ciliary Motility Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Bern · Observational

How we know

From the registry’s dates

  • Started Jan 2013; still recruiting 13 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
800
Sex
All
01

Study summary

The Swiss Primary Ciliary Dyskinesia (PCD) Registry is a national patient registry that collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and international monitoring and research.

Read the detailed description

The Swiss Primary Ciliary Dyskinesia registry (CH-PCD) was founded in 2013 as a collaborative project between epidemiologists and adult and paediatric pulmonologists. It started as a pilot project in the canton of Bern and in 2014 was extended to include all Switzerland. The data centre of the SPCDR is located at the Institute of Social and Preventive Medicine at the University of Bern. It contributes data to the international PCD registry and other international studies such as the international PCD (iPCD) cohort.

Objectives of the CH-PCD:

The Swiss Primary Ciliary Dyskinesia Registry collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and international monitoring and research. In particular, it aims to:

  • Identify all patients diagnosed with PCD in Switzerland.
  • Collect population based data (incidence, prevalence, time trends and regional trends).
  • Document diagnostic evaluations, treatments and participation in clinical trials.
  • Document the clinical course of PCD, quality of life, morbidity and mortality.
  • Establish a research platform for clinical, epidemiological and basic research.

Study design:

The CH-PCD is a patient registry. At baseline (inclusion of a patient to the registry), it collects retrospectively all available data since birth and it follows included patients throughout life until death or loss to follow up, collecting prospectively data at regular time intervals.

What data is collected:

The CH-PCD collects information on demographic characteristics (e.g. age, sex), diagnostic tests and clinical data about manifestations and management of the disease. It collects repeated follow-up data on growth, lung function, clinical manifestations from all affected organ systems, microbiology and imaging, lab results, therapeutic interventions (including surgery and physiotherapy) and hospitalisations. It also collects information on neonatal symptoms related to the disease and on the symptoms, that led to referral and PCD diagnosis.

Since 2020, the CH-PCD collects through questionnaire surveys patient-reported information on symptoms and lifestyle behaviours.

Study database:

The study database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats.

How to participate:

Patients with PCD who would like to participate to the registry as well as physicians who treat patients with PCD should contact the CH-PCD to receive the study information and informed consent forms.

For further details, please contact: spcdr@hin.ch

Funding:

The setting up of the CH-PCD (salaries, consumables and equipment) was funded by several Swiss funding bodies, including the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais and the Kantonalbernischer Hilfsbund.Research activities based on data included in the CH-PCD are funded by the Swiss National Science foundation (SNF 320030_173044, 320030B_192804 and PZ00P3_185923). The CH-PCD participated to the EU funded BEAT-PCD COST Action (BM1407) and participates to the BEAT-PCD clinical research collaboration supported by the European Respiratory Society.

02

Conditions studied

  • Primary Ciliary Dyskinesia
  • Kartagener Syndrome

Browse trials for

03

In context

Kartagener Syndrome Reclassified

21 studies on the registry are indexed under Kartagener Syndrome; 4 are open to participants now.

This study's planned enrollment of 800 is above the median of 200 across 17 observational studies indexed under Kartagener Syndrome.

Browse Kartagener Syndrome studies →

Lead sponsor

University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.

Compared within Kartagener Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ciliary Motility Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients of all ages diagnosed with PCD, who are resident or treated in Switzerland.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with primary ciliary dyskinesia
  • Signed or assent

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
800 participants (estimated)
Target follow-up
80 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Height

    Height z-scores calculated based on available national and international references

    Time frame: every 3 months up to 80 years

  2. BMI

    Body Mass Index (BMI) z-scores calculated based on available national and international references

    Time frame: every 3 months up to 80 years

  3. Lung function measurements

    Spirometric indices, particularly Forced expiratory volume in 1 sec (FEV1) and Forced vital capacity (FVC) z-scores calculated based on Global Lung Function Initiative (GLI) reference values

    Time frame: every 3 months up to 80 years

  4. Measurement of nasal nitric oxide using breath analyzer

    Results of nasal nitric oxide measurement, performed for diagnosis

    Time frame: at study entry (in case patient is <5 years old at study entry, then the outcome will be assessed at age 5

  5. Cilia ultrastructure identified using electron microscopy analysis

    Results of electron microscopy analysis of cilia, performed for diagnosis

    Time frame: at study entry

  6. Ciliary beat frequency and beat pattern using video microscopy analysis

    Results of video microscopy analysis of cilia, performed for diagnosis

    Time frame: at study entry

  7. Microbiological culture of respiratory samples

    Results of microbiology cultures of respiratory samples (sputum, cough swabs, throat swabs, ear swabs, bronchoalveolar lavage) expressed in a qualitative (growth or no growth of pathogens) or semiquantitative way (the type of sample depends on the age of the patient and the clinic the sample was collected).

    Time frame: every 3 months up to 80 years

  8. Antibiotic resistance of microbes isolated in microbiological cultures

    Information on antibiotic resistance of microbes isolated in microbiological cultures (see outcome 7) of respiratory samples, expressed either semiquantitatively or by the value of minimum inhibitory concentration.

    Time frame: every 3 months up to 80 years

  9. Chest computed tomography

    Radiological findings from chest computed tomography

    Time frame: every 3 months up to 80 years

  10. Sinus computed tomography

    Radiological findings from sinus computed tomography

    Time frame: every 3 months up to 80 years

  11. Vital status

    Vital status of patient: has the patient died or is he/she still alive and in case of death what was the cause?

    Time frame: every 3 months up to 80 years

  12. Clinical symptoms frequency

    Frequency of respiratory symptoms recorded with a patient or parent-reported questionnaire

    Time frame: once a year up to 80 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Goutaki M, Eich MO, Halbeisen FS, Barben J, Casaulta C, Clarenbach C, Hafen G, Latzin P, Regamey N, Lazor R, Tschanz S, Zanolari M, Maurer E, Kuehni CE; Swiss PCD Registry (CH-PCD) Working Group. The Swiss Primary Ciliary Dyskinesia registry: objectives, methods and first results. Swiss Med Wkly. 2019 Jan 13;149:w20004. doi: 10.57187/smw.2019.20004. eCollection 2019 Jan 1. PubMed 30691261 ↗
  • Goutaki M, Husler L, Lam YT, Koppe HM, Jung A, Lazor R, Muller L; Swiss PCD Research Group; Pedersen ESL, Kuehni CE. Respiratory symptoms of Swiss people with primary ciliary dyskinesia. ERJ Open Res. 2022 Apr 11;8(2):00673-2021. doi: 10.1183/23120541.00673-2021. eCollection 2022 Apr. PubMed 35415187 ↗
  • Lam YT, Pedersen ESL, Schreck LD, Husler L, Koppe H, Belle FN, Clarenbach C, Latzin P; Swiss PCD research group; Kuehni CE, Goutaki M. Physical activity, respiratory physiotherapy practices, and nutrition among people with primary ciliary dyskinesia in Switzerland - a cross-sectional survey. Swiss Med Wkly. 2022 Aug 18;152:w30221. doi: 10.4414/smw.2022.w30221. eCollection 2022 Aug 15. PubMed 36041191 ↗

Individual participant data

Plan to share: Undecided — Anonymised data are shared for international collaborative projects. For requests related to IPD please contact spcdr@hin.ch

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2013 (actual). Primary completion is estimated for Dec 2080, 815 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2018
First posted
Jul 30, 2018
StartActual
Jan 2013
Primary completionEst.
Dec 2080
CompletionEst.
Dec 2080
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03606200
Lead sponsor
University of Bern
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Jan 2013
Primary completion
Dec 2080 (estimated)
Completion
Dec 2080 (estimated)
Last update
Nov 25, 2025

Study contacts

Claudia E Kuehni, Prof
Contact
spcdr@hin.ch
0041 316313507
Myrofora Goutaki, PD, MD-PhD
Contact
spcdr@hin.ch
0041 316315973
Claudia E Kuehni, Prof
principal investigator · University of Bern
Myrofora Goutaki, PD, MD-PhD
principal investigator · University of Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion